Circulation · 2021
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calabrò Paolo, Gragnano Felice, Niccoli Giampaolo, Marcucci Rossella, Zimarino Marco, Spaccarotella Carmen, Renda Giulia, Patti Giuseppe, Andò Giuseppe, Moscarella Elisabetta, Mancone Massimo, Cesaro Arturo, Giustino Gennaro, De Caterina Raffaele, Mehran Roxana, Capodanno Davide, Valgimigli Marco, Windecker Stephan, Dangas George D, Indolfi Ciro, Angiolillo Dominick J
Аннотация
Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.